Company / Cash & Equivalents
enGene Holdings Inc. Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$50.2M
FY2025
5-year range
$20.4M / $173.0M
FY2022-FY2025
Trend
-71.0%
vs FY2024
Sector context
#178 of 208
Health Care
What the data says
enGene Holdings Inc.'s cash & equivalents of $50M is lower than 86% of companies in the Health Care sector (FY2025). Declined from $82M to $50M over the past 2 years.
Based on SEC 10-K filings.
$50M in FY2025 with a 3-year CAGR of +34.9%.
Declined from $82M to $50M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +34.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 208This company $50.2M Sector average $694.3M
▼
-92.8% below sector average
Key checks
Key Insights
- 3-year CAGR of +34.9%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 71.0% year-over-year.
- Ranks #178 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $50.2M | -71.0% |
| FY2024 | $173.0M | +112.2% |
| FY2023 | $81.5M | +298.9% |
| FY2022 | $20.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026